Acquired Thrombophilia during Pregnancy

Obstetrics and Gynecology Clinics of North America

Volumn 33, Issue 3, 2006, Pages 375-388

  Dentali, Francesco ^a   Crowther, Mark ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOSPORIN; CYSTATHIONINE BETA SYNTHASE; ESTROGEN; FOLIC ACID; HEPARIN; HOMOCYSTEINE; HORMONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; METHIONINE; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PYRIDOXINE; STEROID; UNINDEXED DRUG;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; THROMBOPHILIA; THROMBOSIS; VITAMIN INTAKE;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA;

EID: 33748463053     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2006.05.006     Document Type: Review

References (77)

1. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13 (1965) 516-530
2. Beck E.A., Charache P., and Jackson D.P. A new inherited coagulation disorder caused by an abnormal fibrinogen ('fibrinogen Baltimore'). Nature 208 (1965) 143-145
3. Dahlback B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90 (1993) 1004-1008
4. Crowther M.A., and Kelton J.G. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 138 (2003) 128-134
5. Hague W.M. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol 17 (2003) 459-469
6. Middeldorp S., Buller H.R., Prins M.H., et al. Approach to the thrombophilic patient. In: Colman R.W., Hirsh J., Marder V.J., Clowes A.W., and George J.N. (Eds). Hemostasis and thrombosis: basic principle and clinical practice. 4th edition (2002), Lippincott, Philadelphia 1085-1100
7. Conley C.L., Rathburn H.K., Morse II W.I., et al. Circulating anticoagulant as a cause of hemorrhagic diathesis in man. Bull Hopkins Hosp 83 (1948) 288
8. Bowie E.J., Thompson Jr. J.H., Pascuzzi C.A., et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62 (1963) 416-430
9. Derksen R.H., Hasselaar P., Blokzijl L., et al. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 47 (1988) 364-371
10. Harris E.N., Gharavi A.E., Boey M.L., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2 (1983) 1211-1214
11. Petri M. Epidemiology of the antiphospholipid antibody syndrome. Autoimmunity 15 (2000) 145-151
12. Ginsburg K.S., Liang M.H., Newcomer L., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117 (1992) 997-1002
13. Nilsson I.M., Astedt B., Hedner U., et al. Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Med Scand 197 (1975) 153-159
14. Firkin B.G., Howard M.A., and Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet 2 (1980) 366
15. Carreras L.O., Defreyn G., Machin S.J., et al. Arterial thrombosis, intrauterine death and "lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1 (1981) 244-246
16. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999) 1309-1311
17. Schulman S., Svenungsson E., and Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104 (1998) 332-338
18. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999) 901-907
19. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl (2004) 204S-233S
20. Khamashta M.A., Cuadrado M.J., Mujic F., et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
21. Rosove M.H., and Brewer P.M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117 (1992) 303-308
22. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 (2003) 1133-1138
23. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 (2005) 848-853
24. Lockshin M.D., Druzin M.L., Goei S., et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 313 (1985) 152-156
25. Oshiro B.T., Silver R.M., Scott J.R., et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 87 (1996) 489-493
26. Rand J.H., Wu X.X., Andree H.A., et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med 337 (1997) 154-160
27. di Simone N., Meroni P.L., de Papa N., et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 43 (2000) 140-150
28. Laskin C.A., Bombardier C., Hannah M.E., et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 337 (1997) 148-153
29. Shehata H.A., Nelson-Piercy C., and Khamashta M.A. Management of pregnancy in antiphospholipid syndrome. Rheum Dis Clin N Am 27 (2001) 643-659
30. Cowchock S., and Reece E.A. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing group of the antiphospholipid antibody treatment trial. Am J Obstet Gynecol 176 (1997) 1099-1100
31. Pattison N.S., Chamley L.W., Birdsall M., et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomised controlled trial. Am J Obstet Gynecol 183 (2000) 1008-1012
32. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314 (1997) 253-257
33. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174(5) (1996) 1584-1589
34. Farquharson R.G., Quenby S., and Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 100 3 (2002) 408-413
35. Lepercq J., Conard J., Borel-Derlon A., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 108 (2001) 1134-1140
36. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 (1999) 668-672
37. Walenga J.M., Jeske W.P., Prechel M.M., et al. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost 30 Suppl 1 (2004) 69-80
38. Wawrzynska L., Tomkowski W.Z., Przedlacki J., et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 33 (2003) 64-67
39. Nelson-Piercy C., Letsky E.A., and de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176 (1997) 1062-1068
40. Hall J.G., Pauli R.M., and Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68 (1980) 122-140
41. Schardein J.L. Drug affecting blood. Chemically induced birth defects. 2nd edition (1993), Marcel Dekker, New York 106-125
42. Stevenson R.E., Burton O.M., Ferlauto G.J., et al. Hazards of oral anticoagulants during pregnancy. JAMA 243 (1980) 1549-1551
43. Branch D.W., Peaceman A.M., Druzin M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182 (2000) 122-127
44. Mudd S.H., Levy H.L., and Skovby F. Disorders of transsulfuration. In: Scriver C.R., Beaudet A.L., Sly W.S., Valle D., Stanbury J.B., Wyngarden J.B., and Fredrickson D.S. (Eds). The metabolic and molecular bases of inherited disease (1995), McGraw-Hill, New York 1279-1327
45. Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids 36 Suppl (2001) S13-S26
46. Brattsröm L., Tangborn L., Lagerstedt C., et al. Plasma homocysteine in venous thromboembolism. Haemost 21 (1991) 51-57
47. Bienvenu T., Ankri A., Chadefaux B., et al. Elevated total plasma homocysteine, a risk factor for thrombosis: relation to coagulation and fibrinolytic parameters. Thromb Res 70 (1993) 123-129
48. Falcon C.R., Cattaneo M., Panzeri D., et al. High prevalence of hyperhomocyst (e) inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14 (1994) 1080-1083
49. Petri M., Roubenoff R., Dallal G.E., et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348 (1996) 1120-1124
50. Ridker P.M., Hennekens C.H., Selhub J., et al. Interrelation of hyperhomocyst (e) inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 95 (1997) 1777-1782
51. Cattaneo M., Zighetti M.L., Turner R.M., et al., For the ECAT DVT Study Group. Fasting plasma homocysteine levels do not predict the occurrence of deep-vein thrombosis after elective hip replacement surgery. Neth J Med 52 Suppl (1998) S21
52. den Heijer M., Rosendaal F.R., Blom H.J., et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 80 (1998) 874-877
53. den Heijer M., Lewington S., and Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a metaanalysis of published epidemiological studies. J Thromb Haemost 3 (2005) 292-299
54. Eichinger S., Stumpflen A., Hirschl M., et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80 (1998) 566-569
55. Christiansen S.C., Cannegieter S.C., Koster T., et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 (2005) 2352-2361
56. Andersson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 30 (1992) 377-379
57. Malinow M.R., Rajkovic A., Duell P.B., et al. The relationship between maternal and neonatal umbilical cord plasma homocyst (e) ine suggests a potential role for maternal homocyst(e)ine in fetal metabolism. Am J Obstet Gynecol 178 (1998) 228-233
58. Steegers-Theunissen R.P., Boers G.H., Trijbels F.J., et al. Neural-tube defects and derangement of homocysteine metabolism. N Engl J Med 324 (1991) 199-200
59. Mills J.L., McPartlin J.M., Kirke P.N., et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 345 (1995) 149-151
60. Dekker G.A., de Vries J.I., Doelitzsch P.M., et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 173 (1995) 1042-1048
61. Rajkovic A., Mahomed K., Malinow M.R., et al. Plasma homocyst(e)ine concentrations in eclamptic and preeclamptic African women postpartum. Obstet Gynecol 94 (1999) 355-360
62. Powers R.W., Evans R.W., Majors A.K., et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 179 (1998) 1605-1611
63. Goddijn-Wessel T.A., Wouters M.G., van de Molen E.F., et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 66 (1996) 23-29
64. Owen E.P., Human L., Carolissen A.A., et al. Hyperhomocysteinemia: a risk factor for abruptio placentae. J Inherit Metab Dis 20 (1997) 359-362
65. van der Molen E.F., Verbruggen B., Novakova I., et al. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG 107 (2000) 785-791
66. Ray J.G., and Laskin C.A. Folic acid and homocyst (e) ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 20 (1999) 519-529
67. Wouters M.G., Boers G.H., Blom H.J., et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 60 (1993) 820-825
68. Coumans A.B., Huijgens P.C., Jakobs C., et al. Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Hum Reprod 14 (1999) 211-214
69. Nelen W.L., Blom H.J., and Steegers E.A. Hyperhomocysteinemia and recurrent early pregnancy loss: a metaanalysis. Fertil Steril 74 (2000) 1196-1199
70. Undas A., Brozek J., and Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 94 (2005) 907-915
71. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 316 (1998) 894-898
72. Anonymous. Prevention of neural tube defects: results of the medical research council vitamin study. MRC vitamin study research group. Lancet 338 (1991) 131-137
73. Czeizel A.E., and Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327 (1992) 1832-1835
74. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
75. Lange H., Suryapranata H., De Luca G., et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350 (2004) 2673-2681
76. Leeda M., Riyazi N., de Vries J.I., et al. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol 179 (1998) 135-139
77. Brenner B. Haemostatic changes in pregnancy. Thromb Res 114 (2004) 409-414